# The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases

> **NCT03745196** · PHASE2 · TERMINATED · sponsor: **Pulmocide Ltd** · enrollment: 13 (actual)

## Conditions studied

- Asthma
- Respiratory Candidiasis
- Respiratory Aspergillosis
- COPD
- Bronchiectasis

## Interventions

- **DRUG:** PC945
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03745196
- **Lead sponsor:** Pulmocide Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-11-15
- **Primary completion:** 2020-06-01
- **Final completion:** 2020-06-01
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** The study is being terminated early as a result of the coronavirus (COVID-19) outbreak.
- **Last updated:** 2020-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03745196

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03745196, "The Effect of PC945 on Aspergillus or Candida Lung Infections in Patients With Asthma or Chronic Respiratory Diseases". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03745196. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*